Schneider-Helmert D
Eur Neurol. 1987;27(2):120-9. doi: 10.1159/000116143.
Impaired daytime functions are a significant part of chronic insomnia besides sleep disturbance. Therefore, the effects of intermediate-term delta-sleep-inducing peptide (DSIP) administration on sleep and daytime performance were investigated in 14 middle-aged chronic insomniacs. DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights. Polysomnograms were obtained for placebo baseline, beginning and end of DSIP treatment, and one placebo posttreatment night; daytime psychological state and mental performance were extensively tested before and after 6 DSIP injections. The treatment substantially improved night sleep with the first and additionally with repeated doses. These effects were maintained for the first posttreatment (placebo) night. Efficiency of night sleep and daytime rest reached the levels of normal controls. Alertness and performance at daytime increased significantly. The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.
除睡眠障碍外，日间功能受损是慢性失眠的一个重要部分。因此，在14名中年慢性失眠患者中研究了中期给予δ-睡眠诱导肽（DSIP）对睡眠和日间表现的影响。DSIP在安慰剂对照、双盲条件下连续给药7个晚上。在安慰剂基线、DSIP治疗开始和结束时以及一个安慰剂治疗后晚上记录多导睡眠图；在6次DSIP注射前后对日间心理状态和精神表现进行了广泛测试。首次给药以及重复给药后，治疗显著改善了夜间睡眠。这些效果在治疗后的第一个（安慰剂）晚上得以维持。夜间睡眠效率和日间休息效率达到了正常对照组的水平。日间的警觉性和表现显著提高。该研究证明了DSIP对治疗睡眠受损和日间功能受损同样有效。
